RxDoctor Payments DataLook up a doctor →

Mark Haygood, DO

Psychiatry · Mobile, ALNPI 1073834370

Payments from drug & device makers

$348,236in general payments, 2019–2025

Across 1,322 payments — averaging $263.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$171K
  • Neurocrine Biosciences, Inc.$149K
  • Otsuka America Pharmaceutical, Inc.$18K
  • Teva Pharmaceuticals USA, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Axsome Therapeutics, Inc.$844
  • plus $6K from 26 others

What the payments were for

  • Consulting fees$24,1937%
  • Speaking & faculty fees$282,90981%
  • Travel & lodging$18,7435%
  • Food & beverage$22,1216%
  • Education$2710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$348,236 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$17,445
Medicare patients
32
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$218,198
RexultiBrexpiprazole17$33,352
TrintellixVortioxetine Hydrobromide25$21,463
Aripiprazole19$7,449
Lurasidone Hcl31$6,544
Vilazodone Hcl36$6,292
Lisdexamfetamine Dimesylate22$3,627
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$2,005
Bupropion XlBupropion Hcl69$1,709
Lamotrigine126$1,527
Quetiapine Fumarate92$1,449
Duloxetine Hcl67$1,350
Buspirone Hcl80$880
Haloperidol Decanoate12$858
Clonazepam110$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$149,486$218,19826 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17,949$33,35217 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$621$21,46325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →